View Older Stories View More Recent Stories

Jun 1, 2022 04:45PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022 10:30AM G1 Therapeutics Named 2022 Life Sciences Public Company of the Year by Triangle Business Journal
May 18, 2022 10:15AM G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
May 4, 2022 06:30AM G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
May 2, 2022 05:30PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 21, 2022 08:30AM G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
Apr 6, 2022 11:30AM G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
Apr 1, 2022 04:15PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2022 04:05PM New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Treated with Chemotherapy
Mar 1, 2022 05:00PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 1, 2022 11:15AM G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference
Feb 23, 2022 06:30AM G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Feb 9, 2022 09:15AM G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022
Feb 1, 2022 05:30PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 4, 2022 09:15AM G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C. Wainwright BioConnect Virtual Conferences in January 2022
Jan 3, 2022 05:30PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 16, 2021 06:02AM G1 Therapeutics (GTHX) Expands COSELA Sales Force
Dec 16, 2021 06:00AM G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
Dec 1, 2021 06:20PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 1, 2021 07:00AM G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumor Microenvironment
Nov 29, 2021 07:00AM G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjugate (ADC), Trodelvy® (Sacituzumab Govitecan-Hziy)
Nov 12, 2021 08:25AM G1 Therapeutics (GTHX) Phase 2 Data Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
Nov 12, 2021 08:25AM Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients’ T Cell Immune Function When Administered Prior to Chemotherapy
Nov 11, 2021 07:26PM IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS
Nov 10, 2021 11:40AM G1 Therapeutics to Participate in Two Upcoming Conferences
Nov 3, 2021 06:30AM G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
Nov 1, 2021 06:00PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 20, 2021 08:00AM G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021
Oct 7, 2021 08:00AM Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Care Interventions in Extensive Stage Small Cell Lung Cancer Patients Who Receive th
Oct 1, 2021 04:30PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2021 07:45AM G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
Sep 15, 2021 06:46AM G1 Therapeutics (GTHX) Announces New Supplemental COSELA Sales Force
Sep 15, 2021 06:45AM G1 Therapeutics Announces New Supplemental COSELA™ (Trilaciclib) Sales Force
Sep 3, 2021 07:45AM G1 Therapeutics to Participate in Two Upcoming September Conferences
Sep 3, 2021 07:30AM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 4, 2021 04:01PM G1 Therapeutics Provides Second Quarter 2021 Financial Results and Operational Highlights
Aug 4, 2021 08:00AM G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)
Aug 2, 2021 06:50AM G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer
Jul 28, 2021 08:00AM G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
Jul 19, 2021 09:21AM G1 Therapeutics (GTHX) Receives Fast Track Designation from FDA for COSELA in Combination with Chemotherapy for Treatment of Locally Advanced or Metastatic TNBC
Jul 19, 2021 09:20AM G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic
Jul 15, 2021 04:05PM Viridian Therapeutics Appoints Jennifer Moses, CPA to the Board of Directors and as Chair of the Audit Committee
Jul 2, 2021 07:30PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 18, 2021 09:00AM G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
Jun 16, 2021 07:00AM G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
Jun 14, 2021 07:00AM G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
Jun 4, 2021 04:01PM G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 4, 2021 09:02AM G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Brea
Jun 4, 2021 09:01AM G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
May 19, 2021 05:01PM G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
View More Recent Stories View Older Stories